Research progress of immune-related pneumonia caused by PD-1/PD-L1 inhibitor

doi:10.3760/cma.j.cn371439-20200609-00091

Abstract

Abstract:

The incidence of immune-related pneumonia caused by programmed death-1/programmed death ligand-1 inhibitors is low, but the risk is high. Patients with non-small cell lung cancer who have pre-existing lung diseases or have received chest radiotherapy are more likely to develop pneumonia, but their clinical symptoms are not typical, which reduces the survival benefit of patients. Delaying immunotherapy early and rationally using glucocorticoids and immunosuppressants can relieve clinical symptoms and improve prognosis.

Key words: PD-1, PD-L1, Immune-associated pneumonia

Song Bo, Wu Mingxin, Jia Yingjie, Li Xiaojiang. Research progress of immune-related pneumonia caused by PD-1/PD-L1 inhibitor[J]. Journal of International Oncology, 2020, 47(10): 627-629.

References 24

[1]	Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper[J]. Ann Oncol, 2016,27(4):559-574. DOI: 10.1093/annonc/mdv623.
[2]	Postow MA. Managing immune checkpoint-blocking antibody side effects[J]. Am Soc Clin Oncol Educ Book, 2015: 76-83. DOI: 10.14694/EdBook_AM.2015.35.76. pmid: 25993145
[3]	张宁刚, 尚昆, 曹邦伟. 免疫检查点抑制剂治疗恶性肿瘤的不良反应及处理[J]. 中国医院用药评价与分析, 2018,18(4):435-437. DOI: 10.14009/j.issn.1672-2124.2018.04.002.
[4]	Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis[J]. JAMA Oncol, 2016,2(12):1607-1616. DOI: 10.1001/jamaoncol.2016.2453.
[5]	刘甜, 胡毅. PD-1/PD-L1抑制剂免疫相关性不良反应及其处理综述[J]. 解放军医学院学报, 2018,39(3):251-254. DOI: 10.3969/j.issn.2095-5227.2018.03.018.
[6]	Wu J, Hong D, Zhang X, et al. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis[J]. Sci Rep, 2017,7:44173. DOI: 10.1038/srep44173.
[7]	Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper[J]. Ann Oncol, 2016,27(4):559-574. DOI: 10.1093/annonc/mdv623. doi: 10.1093/annonc/mdv623 pmid: 26715621
[8]	Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017,35(7):709-717. DOI: 10.1200/JCO.2016.68.2005. doi: 10.1200/JCO.2016.68.2005 pmid: 27646942
[9]	Nishino M, Ramaiya NH, Hatabu H, et al. PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy[J]. Br J Haematol, 2018,180(5):752-755. DOI: 10.1111/bjh.14441.
[10]	Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv264-iv266. DOI: 10.1093/annonc/mdy162. pmid: 29917046
[11]	Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy[J]. N Engl J Med, 2015,373(3):288-290. DOI: 10.1056/NEJMc1505197.
[12]	冀寿健, 徐建明. 免疫检查点抑制剂相关不良反应的研究进展[J]. 中国肿瘤临床与康复, 2018,25(7):894-896. DOI: 10.13455/j.cnki.cjcor.2018.07.036.
[13]	Yamaguchi T, Shimizu J, Hasegawa T, et al. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis[J]. Lung Cancer, 2018,125:212-217. DOI: 10.1016/j.lungcan.2018.10.001. doi: 10.1016/j.lungcan.2018.10.001 pmid: 30429022
[14]	Hwang WL, Niemierko A, Hwang KL, et al. Clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy[J]. JAMA Oncol, 2018,4(2):253-255. DOI: 10.1001/jamaoncol.2017.3808.
[15]	Su Q, Zhu EC, Wu JB, et al. Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis[J]. Front Immunol, 2019,10:108. DOI: 10.3389/fimmu.2019.00108. doi: 10.3389/fimmu.2019.00108 pmid: 30778352
[16]	李婧. 以PD-1为代表的免疫检查点分子单抗在肿瘤治疗中的应用研究进展[J]. 细胞与分子免疫学杂志, 2018,34(7):650-654. DOI: 10.13423/j.cnki.cjcmi.008660.
[17]	Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events[J]. Immunotargets Ther, 2017,6:51-71. DOI: 10.2147/ITT.S141577. doi: 10.2147/ITT.S141577 pmid: 28894725
[18]	Sui JD, Wang Y, Wan Y, et al. Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies[J]. Drug Des Devel Ther, 2018,12:1645-1657. DOI: 10.2147/DDDT.S167077.
[19]	闫晨霞, 张然, 王乃栩. 抗PD-1/PD-L1单抗的免疫相关不良反应[J]. 华西药学杂志, 2018,33(3):333-336. DOI: 10.13375/j.cnki.wcjps.2018.03.028.
[20]	彭智, 袁家佳, 王正航, 等. ASCO/NCCN免疫治疗毒性管理指南解读[J]. 肿瘤综合治疗电子杂志, 2018,4(2):38-47.
[21]	Balaji A, Verde F, Suresh K, et al. Pneumonitis from anti-PD-1/PD-L1 therapy[J]. Oncology (Williston Park), 2017,31(10):739-754.
[22]	O'Kane GM, Labbé C, Doherty MK, et al. Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer[J]. Oncologist, 2017,22(1):70-80. DOI: 10.1634/theoncologist.2016-0164.
[23]	中华医学会呼吸病学分会肺癌学组. 免疫检查点抑制剂相关肺炎诊治专家共识[J]. 中华结核和呼吸杂志, 2019,42(11):820-825. DOI: 10.3760/cma.j.issn.1001-0939.2019.11.007.
[24]	Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017,35(7):709-717. DOI: 10.1200/JCO.2016.68.2005. doi: 10.1200/JCO.2016.68.2005 pmid: 27646942